Week in Review: Development of COVID-19 Vaccine AZD1222 Expands to Phase 3 Clinical Trials in the US

Top news of the week from Pharmacy Times®.

5. Help Patients Relieve Mild COVID-19 Symptoms

Although there is still a great deal of uncertainty associated with the global coronavirus disease 2019 (COVID-19) pandemic, frontline health care providers, including pharmacists, remain essential providers of clinical information for patients. Read more.

4. Mandated Immunizations Can Be a Slippery Slope

In this era of the COVID-19 pandemic, questions are resurfacing regarding the validity of state-mandated immunizations. Read more.

3. Ophthalmic Solution Granted FDA Approval for Treatment of Cystinosis

The FDA has approved cysteamine ophthalmic solution 0.37% (Cystadrops, Recordati Rare Diseases, Inc) for the treatment of patients living with cystinosis. Read more.

2. Development of COVID-19 Vaccine AZD1222 Expands to Phase 3 Clinical Trials in the US

The development of the COVID-19 vaccine AZD1222 has expanded into a phase 3 trial that is enrolling 30,000 adults aged 18 years or older to assess its safety, efficacy, and immunogenicity. Read more.

1. Many Americans Do Not Follow Proper Health, Hygiene Practices

Two surveys conducted by the American Cleaning Institute and ValuePenguin found that although Americans are concerned about their health, many do not adhere to proper health and hygiene practices. Read here.